adrenergic receptor agonist. Inhibits the release of histamine, leukotrienes and prostaglandin D2
, and blocks GM-CSF production from human cultured mast cells. Exhibits efficacious bronchodilatory activity in patients with asthma or chronic obstructive pulmonary disease (COPD).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Effects of salmeterol xinafoate and fluticasone propionate on immunological activation of human cultured mast cells.
Akabane et al.
Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
Rennard et al.
Am.J.Respir.Crit.Care Med., 2001;163:1087
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma.
Roberts et al.
The citations listed below are publications that use Tocris products. Selected citations for Salmeterol xinafoate include:
Showing Results 1 - 4 of 4